CD73 and adenosine have gained prominence in lung cancer research. TheNT5Egene encodes CD73, known as an ectonucleotidase, which plays a crucial role within tumor cells, with immune-suppressive properties. Beyond cancer, CD73 exerts an influence on cardiac, neural, and renal functions, affecting cardiac, neural, and renal functions. CD73’s significance lies in its production of extracellular adenosine. It is notably expressed across diverse cell types within the immune and stromal lung microenvironment. CD73 expression amplifies in lung tumors, especially non-small cell lung cancer (NSCLC), often aligned with key oncogenic drivers like mutantEGFRandKRAS. CD73/adenosine pathway seems to be involved in tumoral immunoevasion, hampering the use of the immune checkpoint inhibitor (ICI) and correlating with therapy resistance. Despite the partial success of current ICI therapies, the CD73/adenosine pathway offers promise in enhancing their effectiveness. This comprehensive review explores recent insights into lung cancer’s CD73/adenosine pathway. It explores roles within tumor cells, the lung’s stromal environment, and the immune system. Ranging from pre-clinical models to clinical trials, potential therapies targeting the adenosine pathway for lung cancer treatment are discussed below.
CD73与腺苷在肺癌研究领域日益受到重视。NT5E基因编码的CD73作为一种外核苷酸酶，在肿瘤细胞内发挥关键作用并具有免疫抑制特性。除癌症外，CD73对心、脑、肾功能亦产生重要影响。其核心生物学意义在于介导细胞外腺苷的生成，并在肺免疫微环境及基质微环境的各种细胞类型中广泛表达。CD73在肺肿瘤（尤其非小细胞肺癌）中表达显著增强，常与EGFR、KRAS等关键致癌驱动基因突变共存。CD73/腺苷通路参与肿瘤免疫逃逸过程，可能影响免疫检查点抑制剂疗效并与治疗耐药相关。尽管当前免疫检查点抑制剂疗法仅取得部分成功，但靶向CD73/腺苷通路有望提升其治疗效果。本综述系统探讨肺癌CD73/腺苷通路的最新研究进展，涵盖其在肿瘤细胞、肺基质微环境及免疫系统中的作用机制，并从临床前模型到临床试验多维度阐述靶向腺苷通路治疗肺癌的潜在策略。
肿瘤(癌症)患者之家